Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR2 | Q8TDS4 | 11/20 | 0.60 |
| ▸ | HCAR3 | P49019 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | CASP7 | P55210 | 1/20 | 0.36 |
| ▸ | CASP6 | P55212 | 1/20 | 0.36 |
| ▸ | HAO1 | Q9UJM8 | 1/20 | 0.35 |
| ▸ | CDC25B | P30305 | 3/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6365547 | 0.87 | HCAR2 (0.48) | HCAR2HCAR3MAPTALDH1A1CASP7 | |
| SCHEMBL1558736 | 0.84 | HCAR2 (0.57) | HCAR2MAPTALDH1A1CASP7CASP6 | |
| SCHEMBL6366344 | 0.79 | HCAR2 (0.42) | HCAR2MAPTALDH1A1CASP7CASP6 | |
| SCHEMBL3956709 | 0.75 | HCAR2 (1.00) | HCAR2HCAR3HAO1 | |
| SCHEMBL27468546 | 0.73 | HCAR2 (0.40) | HCAR2HCAR3MAPTALDH1A1CASP7 | |
| SCHEMBL1559276 | 0.73 | MAPT (0.53) | HCAR2MAPTALDH1A1CASP7CASP6 | |
| SCHEMBL6363165 | 0.71 | HCAR2 (0.44) | HCAR2MAPTALDH1A1CASP7CASP6 | |
| SCHEMBL11411101 | 0.71 | HCAR2 (0.65) | HCAR2HCAR3HAO1 | |
| SCHEMBL331274 | 0.71 | ALDH1A1 (0.36) | HCAR2MAPTALDH1A1CASP7CASP6 | |
| SCHEMBL11365654 | 0.70 | HCAR2 (0.59) | HCAR2HCAR3HAO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6967204-B2 | Treatment of insulin resistance syndrome and type 2 diabetes with PDE9 inhibitors | PFIZER INC (US) | 2005-11-22 | — | — | US | disclosed |
| US-20050070557-A1 | Treatment of insulin resistance syndrome and type 2 diabetes with PDE9 inhibitors | PFIZER INC | 2005-03-31 | — | — | US | disclosed |
| CN-1575191-A | Treatment of insulin resistance syndrome and type 2 diabetes with PDE9 inhibitors | PFIZER PROD INC (US) | 2005-02-02 | — | — | CN | disclosed |
| EP-1444009-A1 | TREATMENT OF INSULIN RESISTANCE SYNDROME AND TYPE 2 DIABETES WITH PDE9 INHIBITORS | Pfizer Products Inc. (US) | 2004-08-11 | — | — | EP | disclosed |
| US-20040023989-A1 | Treatment of insulin resistance syndrome and type 2 diabetes with PDE9 inhibitors | FRYBURG DAVID A (US) | 2004-02-05 | — | — | US | disclosed |
| WO-2003037432-A1 | TREATMENT OF INSULIN RESISTANCE SYNDROME AND TYPE 2 DIABETES WITH PDE9 INHIBITORS | PFIZER PRODUCTS INC. (US) | 2003-05-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050070557-A1 | Treatment of insulin resistance syndrome and type 2 diabetes with PDE9 inhibitors | GPR119, PDE2A, PDE9A | HCAR2 1033/4885HCAR3 2113/4885MAPT 4748/4885 |
| US-20040023989-A1 | Treatment of insulin resistance syndrome and type 2 diabetes with PDE9 inhibitors | GPR119, PDE2A, PDE9A | HCAR2 1033/4885HCAR3 2113/4885MAPT 4748/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.